Manufacturing - Tools & Accessories
Compare Stocks
5 / 10Stock Comparison
LECO vs EMR vs AME vs NDSN vs ROP
Revenue, margins, valuation, and 5-year total return — side by side.
Industrial - Machinery
Industrial - Machinery
Industrial - Machinery
Industrial - Machinery
LECO vs EMR vs AME vs NDSN vs ROP — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Manufacturing - Tools & Accessories | Industrial - Machinery | Industrial - Machinery | Industrial - Machinery | Industrial - Machinery |
| Market Cap | $14.86B | $79.02B | $53.72B | $15.83B | $36.28B |
| Revenue (TTM) | $4.35B | $18.32B | $7.60B | $2.85B | $8.12B |
| Net Income (TTM) | $538M | $2.44B | $1.53B | $523M | $1.71B |
| Gross Margin | 36.1% | 52.7% | 36.6% | 55.2% | 69.4% |
| Operating Margin | 17.1% | 19.8% | 26.2% | 25.9% | 28.1% |
| Forward P/E | 24.7x | 21.7x | 28.6x | 24.8x | 16.1x |
| Total Debt | $1.29B | $13.76B | $2.28B | $2.09B | $9.30B |
| Cash & Equiv. | $309M | $1.54B | $458M | $108M | $297M |
LECO vs EMR vs AME vs NDSN vs ROP — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Lincoln Electric Ho… (LECO) | 100 | 329.9 | +229.9% |
| Emerson Electric Co. (EMR) | 100 | 231.5 | +131.5% |
| AMETEK, Inc. (AME) | 100 | 253.4 | +153.4% |
| Nordson Corporation (NDSN) | 100 | 150.5 | +50.5% |
| Roper Technologies,… (ROP) | 100 | 87.2 | -12.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: LECO vs EMR vs AME vs NDSN vs ROP
Each card shows where this stock fits in a portfolio — not just who wins on paper.
LECO is the #2 pick in this set and the best alternative if valuation efficiency and defensive is your priority.
- PEG 1.11 vs EMR's 4.81
- Beta 1.13, yield 1.1%, current ratio 1.82x
- 14.2% ROA vs ROP's 5.0%, ROIC 22.7% vs 6.1%
EMR ranks third and is worth considering specifically for income & stability.
- Dividend streak 37 yrs, beta 1.52, yield 1.5%
- 1.5% yield, 37-year raise streak, vs NDSN's 1.1%
AME is the clearest fit if your priority is long-term compounding and sleep-well-at-night.
- 423.4% 10Y total return vs LECO's 389.7%
- Lower volatility, beta 0.93, Low D/E 21.5%, current ratio 1.06x
NDSN is the clearest fit if your priority is momentum.
- +51.8% vs ROP's -38.0%
ROP carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth 12.3%, EPS growth -1.0%, 3Y rev CAGR 13.7%
- 12.3% revenue growth vs EMR's 3.0%
- Lower P/E (16.1x vs 24.8x)
- 21.1% margin vs LECO's 12.4%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 12.3% revenue growth vs EMR's 3.0% | |
| Value | Lower P/E (16.1x vs 24.8x) | |
| Quality / Margins | 21.1% margin vs LECO's 12.4% | |
| Stability / Safety | Beta 0.43 vs EMR's 1.52, lower leverage | |
| Dividends | 1.5% yield, 37-year raise streak, vs NDSN's 1.1% | |
| Momentum (1Y) | +51.8% vs ROP's -38.0% | |
| Efficiency (ROA) | 14.2% ROA vs ROP's 5.0%, ROIC 22.7% vs 6.1% |
LECO vs EMR vs AME vs NDSN vs ROP — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
LECO vs EMR vs AME vs NDSN vs ROP — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ROP leads in 2 of 6 categories
LECO leads 1 • EMR leads 1 • AME leads 0 • NDSN leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ROP leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
EMR is the larger business by revenue, generating $18.3B annually — 6.4x NDSN's $2.8B. ROP is the more profitable business, keeping 21.1% of every revenue dollar as net income compared to LECO's 12.4%. On growth, LECO holds the edge at +11.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $4.3B | $18.3B | $7.6B | $2.8B | $8.1B |
| EBITDAEarnings before interest/tax | $845M | $4.7B | $2.3B | $851M | $3.2B |
| Net IncomeAfter-tax profit | $538M | $2.4B | $1.5B | $523M | $1.7B |
| Free Cash FlowCash after capex | $438M | $3.1B | $1.7B | $646M | $2.6B |
| Gross MarginGross profit ÷ Revenue | +36.1% | +52.7% | +36.6% | +55.2% | +69.4% |
| Operating MarginEBIT ÷ Revenue | +17.1% | +19.8% | +26.2% | +25.9% | +28.1% |
| Net MarginNet income ÷ Revenue | +12.4% | +13.3% | +20.1% | +18.4% | +21.1% |
| FCF MarginFCF ÷ Revenue | +10.1% | +17.0% | +22.4% | +22.7% | +31.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | +11.6% | +2.9% | +11.3% | +8.8% | +11.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +17.6% | +28.2% | +14.5% | +44.2% | +59.1% |
Valuation Metrics
ROP leads this category, winning 5 of 7 comparable metrics.
Valuation Metrics
At 24.8x trailing earnings, ROP trades at a 32% valuation discount to AME's 36.6x P/E. Adjusting for growth (PEG ratio), LECO offers better value at 1.31x vs EMR's 7.73x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $14.9B | $79.0B | $53.7B | $15.8B | $36.3B |
| Enterprise ValueMkt cap + debt − cash | $15.8B | $91.2B | $55.5B | $17.8B | $45.3B |
| Trailing P/EPrice ÷ TTM EPS | 29.09x | 34.92x | 36.64x | 33.39x | 24.82x |
| Forward P/EPrice ÷ next-FY EPS est. | 24.71x | 21.71x | 28.56x | 24.80x | 16.08x |
| PEG RatioP/E ÷ EPS growth rate | 1.31x | 7.73x | 3.28x | 2.26x | 2.59x |
| EV / EBITDAEnterprise value multiple | 19.48x | 18.07x | 29.55x | 20.66x | 14.57x |
| Price / SalesMarket cap ÷ Revenue | 3.51x | 4.39x | 7.26x | 5.67x | 4.59x |
| Price / BookPrice ÷ Book value/share | 10.31x | 3.94x | 5.10x | 5.31x | 1.91x |
| Price / FCFMarket cap ÷ FCF | 27.82x | 29.63x | 32.14x | 23.94x | 14.55x |
Profitability & Efficiency
LECO leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
LECO delivers a 37.3% return on equity — every $100 of shareholder capital generates $37 in annual profit, vs $9 for ROP. AME carries lower financial leverage with a 0.21x debt-to-equity ratio, signaling a more conservative balance sheet compared to LECO's 0.88x. On the Piotroski fundamental quality scale (0–9), EMR scores 7/9 vs ROP's 6/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +37.3% | +12.1% | +14.4% | +16.8% | +8.8% |
| ROA (TTM)Return on assets | +14.2% | +5.8% | +9.6% | +10.2% | +5.0% |
| ROICReturn on invested capital | +22.7% | +8.2% | +12.1% | +10.5% | +6.1% |
| ROCEReturn on capital employed | +26.2% | +10.0% | +15.0% | +13.4% | +7.7% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 7 | 7 | 6 | 6 |
| Debt / EquityFinancial leverage | 0.88x | 0.68x | 0.21x | 0.69x | 0.47x |
| Net DebtTotal debt minus cash | $985M | $12.2B | $1.8B | $2.0B | $9.0B |
| Cash & Equiv.Liquid assets | $309M | $1.5B | $458M | $108M | $297M |
| Total DebtShort + long-term debt | $1.3B | $13.8B | $2.3B | $2.1B | $9.3B |
| Interest CoverageEBIT ÷ Interest expense | 12.38x | 6.46x | 23.34x | 7.44x | 6.50x |
Total Returns (Dividends Reinvested)
Evenly matched — EMR and NDSN each lead in 2 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in LECO five years ago would be worth $21,237 today (with dividends reinvested), compared to $8,255 for ROP. Over the past 12 months, NDSN leads with a +51.8% total return vs ROP's -38.0%. The 3-year compound annual growth rate (CAGR) favors EMR at 20.7% vs ROP's -7.6% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +11.5% | +4.3% | +12.3% | +18.2% | -18.5% |
| 1-Year ReturnPast 12 months | +51.1% | +30.4% | +38.9% | +51.8% | -38.0% |
| 3-Year ReturnCumulative with dividends | +65.1% | +75.9% | +64.1% | +34.5% | -21.0% |
| 5-Year ReturnCumulative with dividends | +112.4% | +59.5% | +74.5% | +42.4% | -17.5% |
| 10-Year ReturnCumulative with dividends | +389.7% | +206.6% | +423.4% | +298.2% | +115.0% |
| CAGR (3Y)Annualised 3-year return | +18.2% | +20.7% | +18.0% | +10.4% | -7.6% |
Risk & Volatility
Evenly matched — AME and ROP each lead in 1 of 2 comparable metrics.
Risk & Volatility
ROP is the less volatile stock with a 0.43 beta — it tends to amplify market swings less than EMR's 1.52 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AME currently trades 96.4% from its 52-week high vs ROP's 60.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.12x | 1.52x | 0.94x | 1.04x | 0.39x |
| 52-Week HighHighest price in past year | $310.00 | $165.15 | $243.18 | $305.28 | $584.03 |
| 52-Week LowLowest price in past year | $180.17 | $108.37 | $168.49 | $188.22 | $313.86 |
| % of 52W HighCurrent price vs 52-week peak | +87.5% | +85.4% | +96.4% | +93.1% | +60.3% |
| RSI (14)Momentum oscillator 0–100 | 63.6 | 61.3 | 63.3 | 59.3 | 43.6 |
| Avg Volume (50D)Average daily shares traded | 348K | 2.8M | 1.2M | 306K | 1.2M |
Analyst Outlook
EMR leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: LECO as "Hold", EMR as "Buy", AME as "Buy", NDSN as "Buy", ROP as "Buy". Consensus price targets imply 29.8% upside for ROP (target: $458) vs 5.6% for AME (target: $248). For income investors, EMR offers the higher dividend yield at 1.49% vs AME's 0.53%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $301.71 | $161.92 | $247.73 | $311.50 | $457.64 |
| # AnalystsCovering analysts | 22 | 41 | 29 | 20 | 23 |
| Dividend YieldAnnual dividend ÷ price | +1.1% | +1.5% | +0.5% | +1.1% | +0.9% |
| Dividend StreakConsecutive years of raises | 12 | 37 | 16 | 37 | 12 |
| Dividend / ShareAnnual DPS | $3.01 | $2.10 | $1.23 | $3.15 | $3.29 |
| Buyback YieldShare repurchases ÷ mkt cap | +2.3% | +1.6% | +0.8% | +1.9% | +1.4% |
ROP leads in 2 of 6 categories (Income & Cash Flow, Valuation Metrics). LECO leads in 1 (Profitability & Efficiency). 2 tied.
LECO vs EMR vs AME vs NDSN vs ROP: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is LECO or EMR or AME or NDSN or ROP a better buy right now?
For growth investors, Roper Technologies, Inc.
(ROP) is the stronger pick with 12. 3% revenue growth year-over-year, versus 3. 0% for Emerson Electric Co. (EMR). Roper Technologies, Inc. (ROP) offers the better valuation at 24. 8x trailing P/E (16. 1x forward), making it the more compelling value choice. Analysts rate Emerson Electric Co. (EMR) a "Buy" — based on 41 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — LECO or EMR or AME or NDSN or ROP?
On trailing P/E, Roper Technologies, Inc.
(ROP) is the cheapest at 24. 8x versus AMETEK, Inc. at 36. 6x. On forward P/E, Roper Technologies, Inc. is actually cheaper at 16. 1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Lincoln Electric Holdings, Inc. wins at 1. 11x versus Emerson Electric Co. 's 4. 81x — a reasonable growth-adjusted valuation.
03Which is the better long-term investment — LECO or EMR or AME or NDSN or ROP?
Over the past 5 years, Lincoln Electric Holdings, Inc.
(LECO) delivered a total return of +112. 4%, compared to -17. 5% for Roper Technologies, Inc. (ROP). Over 10 years, the gap is even starker: AME returned +418. 8% versus ROP's +109. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — LECO or EMR or AME or NDSN or ROP?
By beta (market sensitivity over 5 years), Roper Technologies, Inc.
(ROP) is the lower-risk stock at 0. 39β versus Emerson Electric Co. 's 1. 52β — meaning EMR is approximately 286% more volatile than ROP relative to the S&P 500. On balance sheet safety, AMETEK, Inc. (AME) carries a lower debt/equity ratio of 21% versus 88% for Lincoln Electric Holdings, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — LECO or EMR or AME or NDSN or ROP?
By revenue growth (latest reported year), Roper Technologies, Inc.
(ROP) is pulling ahead at 12. 3% versus 3. 0% for Emerson Electric Co. (EMR). On earnings-per-share growth, the picture is similar: Emerson Electric Co. grew EPS 17. 8% year-over-year, compared to -1. 0% for Roper Technologies, Inc.. Over a 3-year CAGR, ROP leads at 13. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — LECO or EMR or AME or NDSN or ROP?
AMETEK, Inc.
(AME) is the more profitable company, earning 20. 0% net margin versus 12. 3% for Lincoln Electric Holdings, Inc. — meaning it keeps 20. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ROP leads at 28. 3% versus 16. 9% for LECO. At the gross margin level — before operating expenses — ROP leads at 69. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is LECO or EMR or AME or NDSN or ROP more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Lincoln Electric Holdings, Inc. (LECO) is the more undervalued stock at a PEG of 1. 11x versus Emerson Electric Co. 's 4. 81x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Roper Technologies, Inc. (ROP) trades at 16. 1x forward P/E versus 28. 6x for AMETEK, Inc. — 12. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ROP: 29. 8% to $457. 64.
08Which pays a better dividend — LECO or EMR or AME or NDSN or ROP?
All stocks in this comparison pay dividends.
Emerson Electric Co. (EMR) offers the highest yield at 1. 5%, versus 0. 5% for AMETEK, Inc. (AME).
09Is LECO or EMR or AME or NDSN or ROP better for a retirement portfolio?
For long-horizon retirement investors, Roper Technologies, Inc.
(ROP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 39), 0. 9% yield, +109. 8% 10Y return). Emerson Electric Co. (EMR) carries a higher beta of 1. 52 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ROP: +109. 8%, EMR: +206. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between LECO and EMR and AME and NDSN and ROP?
Both stocks operate in the Industrials sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.